Yong-Qian Shu

Nanjing Medical University - Department of Oncology

China

SCHOLARLY PAPERS

2

DOWNLOADS

61

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Number of pages: 40 Posted: 20 Jan 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Beijing Cancer Hospital, Nanjing Medical University - Department of Oncology, Fudan University, Harbin Medical University - Cancer Hospital, Guangzhou Medical University - First Affiliated Hospital, Jilin University (JLU) - First Affiliated Hospital, Government of the People's Republic of China - 307th Hospital, Central South University - Hunan Cancer Hospital, Tongji University - Shanghai Pulmonary Hospital, Soochow University - First Affiliated Hospital, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - China and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 38 (548,867)

Abstract:

Loading...

Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET

2.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Number of pages: 56 Posted: 19 Dec 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Jilin Provincial Tumor Hospital - Department of Thoracic Oncology, China Medical University - Department of Medical Oncology, Harbin Medical University - Cancer Hospital, Jilin University (JLU) - The Cancer Center, Central South University - Department of Medical Oncology, Nanjing Military General Hospital - Respiratory Medicine, China Medical University - Medical Oncology Department of Thoracic Cancer, Shanghai Jiao Tong University (SJTU) - Medical Oncology, Zhejiang University - Respiratory Medicine, Henan Cancer Hospital - Respiratory Medicine, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Medical Oncology, Fujian Cancer Hospital - Medical Oncology, Nanjing Medical University - Department of Oncology and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 23 (638,104)
Citation 1

Abstract:

Loading...

bevacizumab, EGFR mutation, epidermal growth factor inhibitor, erlotinib, non-small-cell lung cancer, vascular endothelial growth factor inhibitor